Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Increase in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 271,866 shares, an increase of 715.0% from the August 31st total of 33,356 shares. Based on an average trading volume of 20,006,870 shares, the days-to-cover ratio is presently 0.0 days. Currently, 26.5% of the company’s shares are sold short.

Biodexa Pharmaceuticals Stock Performance

Biodexa Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, hitting $0.68. 126,594 shares of the company were exchanged, compared to its average volume of 10,626,635. The company’s fifty day moving average price is $1.23 and its 200-day moving average price is $2.61. Biodexa Pharmaceuticals has a fifty-two week low of $0.61 and a fifty-two week high of $59.40.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, September 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines drug candidates with proprietary delivery technologies intended to improve how therapies are administered, distributed, or released in the body.

Biodexa’s pipeline has included MTX110, a liquid formulation of the cancer medicine panobinostat being investigated for direct administration into brain tumors, including diffuse midline glioma.